Jiangsu Bochuang Biotechnology

Based in Suzhou, Jiangsu, Jiangsu Bochuang Biotechnology Co., Ltd. is a developer of therapeutic devices and biotechnology products. The company was established in 2022 and operates within the life sciences and therapeutic devices industries.

The firm's core focus is on creating biological tissues and derivative medical device products to address needs in alveolar bone, membrane, and diseased cornea repair within the Chinese market. Its product pipeline is built upon a proprietary technology platform known as "biological macromolecule electrochemical deposition" (EDP). This has led to the development of a range of products including an artificial cornea, periosteum, dura mater, and nerve sheaths, all designed to offer restorative therapies for patients. The company is also described as a developer of high-end biological tissue functional membranes.

Since its inception, Jiangsu Bochuang Biotechnology has progressed through several funding stages. It secured a seed round of $1.45 million on March 17, 2023. This was followed by an early-stage venture capital round on August 10, 2023, with participation from investors including Suzhou Jiasheng Venture Capital and Christine International Holdings. A third early-stage VC round was completed on December 12, 2024. Other disclosed investors in the company include Bangming Capital, Holley Group Investment, Leader Venture Capital, and TigerYeah Capital. The company is currently private, venture capital-backed, and generating revenue.

Keywords: Therapeutic devices, biotechnology, biological tissues, medical devices, cornea repair, alveolar bone repair, biological macromolecule electrochemical deposition, artificial cornea, periosteum, dura mater, nerve sheath, restorative therapies, life sciences, venture capital, medical repair